FDA Acceptance of Foreign Clinical Studies

FDA Acceptance of Foreign Clinical Studies (21 CFR 312.120)

FDA Acceptance of Foreign Clinical Studies

Today, most clinical trials aren't confined to a single country. Sponsors often conduct trials across multiple countries and, in some cases, rely entirely on foreign data to support marketing applications in the United States.

But here's the key question: Will the FDA accept foreign study data if the trial wasn't conducted under an IND (Investigational New Drug application)?

The answer lies in 21 CFR 312.120, a regulation designed to ensure patient protection and data credibility in studies conducted outside the U.S.

Why it Matters?

FDA will accept a foreign trial not conducted under an IND if:

• The study was conducted in Good Clinical Practice (GCP), covering design, conduct, monitoring, auditing, reporting, informed consent, and independent ethics committee (IEC) review.
• FDA can validate the data (through an inspection, if necessary).

The regulation aligns with global standards like ICH E6 (Good Clinical Practice), helping harmonize trial conduct across regions while safeguarding patient rights. If these conditions aren't met, the FDA won't rely on the data for approval, though they may still review it for safety insights.

Key FDA Requirements (21 CFR 312.120)

Sponsors must provide sufficient documentation to demonstrate that the foreign study adhered to GCP. Here are the 11 critical elements FDA expects:

1. Investigator Qualifications
   • Provide CVs, training records, and relevant clinical experience.
   • For novel or high-risk therapies, FDA expects detailed evidence of investigator expertise.
2. Description of Research Facilities
   • Include details on resources, equipment, and emergency care capacity, alongside the name and address.
3. Protocol and Results Summary and Case Records
   • A full Clinical Study Report (CSR) following ICH E3.
   • FDA may require access to original hospital/clinical records to validate data.
4. Product Information
   • Components and specifications of the product.
5. Evidence of Adequate and Well-Controlled Study Design
   • Proof that the trial met the FDA's standards under 21 CFR 314.126
   • Demonstration of the applicability of foreign data to the U.S. population and medical practice.
6. Independent Ethics Committee (IEC) Information
   • Provide the IEC name and address, plus a statement confirming it meets FDA's definition of an adequately constituted ethics committee.
   • Sponsors must maintain records of IEC membership and qualifications (even if not submitted directly).
7. IEC Decisions
   • Summarize approvals, modifications, and key dates.
   • Continuing review records must be retained though not routinely submitted.
8. Informed Consent Process
   • Describe how consent was obtained, consistent with ICH E6 principles.
9. Subject Incentives
   • Provide either a sample consent form showing compensation or a narrative description of incentives.
10. Sponsor Oversight & Monitoring
    • Document how the study was monitored and audited to ensure protocol adherence.
11. Investigator Training & Commitments
    • Evidence showing how investigators were trained in GCP and the study protocol.

Waivers and Flexibility

FDA recognizes that in certain countries, privacy laws or local regulations may restrict access to IEC member names or hospital records. In such cases, sponsors can request a waiver under 21 CFR 312.120(c), providing:

1. Why compliance is impossible or unnecessary,
2. An alternative approach, or
3. Other justification.

Record Retention

Sponsors must retain records for:

• At least 2 years after FDA's decision on a marketing application, or
• 2 years after the IND submission, if the data are not used in a marketing application.

Steps for Sponsors

 

Conclusion

Global clinical trials offer enormous opportunities to accelerate drug development and bring therapies to patients worldwide. However, sponsors must ensure that foreign data meet the FDA's standards for ethics, quality, and reliability.

By adhering to the requirements of 21 CFR 312.120, sponsors can confidently leverage non-IND foreign studies to support U.S. submissions, ultimately helping innovative treatments reach patients faster while maintaining the highest standards of protection for research participants.